Compare NetEase Inc (NTES) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Recursion Pharmaceuticals Inc — how do they compare? NetEase Inc trades at $124.29 (market cap $83.89B), while Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B). The key difference: NetEase Inc is far larger — about 47.1× Recursion Pharmaceuticals Inc's market cap, and NetEase Inc pays a 2.26% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NTES | RXRX | |
|---|---|---|
Market Cap | $83.89B | $1.78B |
Sector | Media | Health |
52-Week High | $159.34 | $6.79 |
52-Week Low | $109.26 | $2.84 |
Enterprise Value | $60.18B | $1.30B |
Dividend Yield | 2.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTES trades at $132.22, up 1.43% today, with a bullish technical signal from moving averages and support near $131. The company reported Q1 2026 EPS of $2.53, beating estimates, and maintains strong profitability with a 29.84% net income margin. Recent news highlights upcoming Q2 2026 earnings on August 20, 2026, amid positive sentiment for Chinese tech stocks.
Outlook is positive with 82% analyst buy ratings and a 34.7% upside potential, though risks include earnings volatility and regulatory pressures. Revenue growth to $114.4B in 2026 and robust cash flow support valuation, but investors should monitor execution amid competitive and macroeconomic challenges.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
